Clinical Trials Logo

Clinical Trial Summary

Total mesorectal excision (TME) is a precise dissection of the rectum and all para-rectal lymph nodes within the mesorectal envelope. It is becoming universally recognized and accepted as the standard technique for surgical excision of rectum carcinomas. TME results in lowest rates of local recurrence, especially when combined with pre-operative chemo-radiotherapy.

Especially after pre-operative chemo-radiotherapy, the post-operative drainage may be important. The quick decrease of this drainage will enable the early mobilisation of the patient and may shorten the time of hospitalization. If this decrease in fluid production can be achieved, it will have a positive effect on the Quality of Life of the patient and will ensure health economic savings by reduction of hospitalization time and resources.

Somatostatin analogues have shown to be able to decrease the secretion of numerous types of bodily fluids.

The aim of this study is to investigate if lanreotide Autogel 120mg is capable to reduce the fluid discharge in patients that underwent a TME for rectumcarcinoma.

Lanreotide Autogel 120mg compared to placebo, administered post-surgery on the fluid discharge in the drain of the patient that underwent a total mesorectum excision (TME) for rectal carcinoma. Patient planned to have a TME will be asked to participate in the study. When they have provided written informed consent, they will be randomized 1:1 to receive either placebo or lanreotide autogel 120mg. Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication or placebo will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards. If the patient has a hematocrit >10% in his drain fluid for a period of 5 days, this patient can not be randomized.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01372007
Study type Interventional
Source University Hospital, Ghent
Contact
Status Completed
Phase Phase 3
Start date July 2011
Completion date December 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01227239 - Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting Phase 1/Phase 2
Recruiting NCT01459328 - Resource-Sparing Curative Treatment for Rectal Cancer Phase 3
Recruiting NCT04078828 - PR in Endoscopic LAR for Rectal Cancer N/A
Not yet recruiting NCT06424522 - A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients Early Phase 1
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Completed NCT01751516 - PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
Terminated NCT01111292 - Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia Phase 1/Phase 2
Completed NCT00682786 - Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma Phase 2
Completed NCT02000050 - Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE) Phase 2
Recruiting NCT04749108 - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Phase 2/Phase 3
Active, not recruiting NCT01696981 - Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial) N/A
Active, not recruiting NCT01899547 - Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum N/A
Completed NCT01333709 - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma Phase 2
Recruiting NCT04848311 - Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253 N/A
Not yet recruiting NCT02770911 - Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer Phase 3
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Active, not recruiting NCT02817126 - Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer N/A
Completed NCT02551237 - Neoadjuvant Treatment for Advanced Rectal Carcinoma Phase 3
Active, not recruiting NCT04713618 - Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy